andexanet alfa
Trade name: Andexxa
Recombinant proteinexperimental
Clinical trial activity
15 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
11
Phase 3
5
Phase 4
1
Earliest trial started Jun 30, 2012 (NCT03218241)
Timeline
Indications
Approved for
Mechanism of action
- Tissue factor pathway inhibitorINHIBITOR
Tissue factor pathway inhibitor inhibitor
In addition to functioning as a decoy agent for the anticoagulant medicines apixaban or rivaroxaban, ANDEXANET ALFA can also inhibit tissue factor pathway inhibitor.
- RivaroxabanSEQUESTERING AGENT
Rivaroxaban sequestering agent
Decoy agent for anticoagulant medicines apixaban or rivaroxaban.
- ApixabanSEQUESTERING AGENT
Apixaban sequestering agent
Decoy agent for anticoagulant medicines apixaban or rivaroxaban.
- Coagulation factor XSupplementation
F10 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Black box warning
Sources
- NCATSBI009E452R ↗
- ChEMBLCHEMBL3301583 ↗
Also known as
- adenexanet alfa
- andexanet
- andexanet
- andexanet alfa
- andexanet alfa
- andexanet alfa
- prt064445
- prt064445
- prt-064445
- prt4445
- prt-4445
- r-antidote
- rfxa inhibitor antidote
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07312851 | Phase 1 | Jan 12, 2026 | AstraZeneca, Parexel |
| NCT05926349 | Phase 3 | Oct 20, 2023 | AstraZeneca |
| NCT04233073 | Phase 3 | Dec 13, 2019 | Portola Pharmaceuticals |
| NCT03661528 | Phase 4 | Jan 1, 2019 | McMaster University, Portola Pharmaceuticals |
| NCT03310021 | Phase 2 | Aug 28, 2017 | Portola Pharmaceuticals |
| NCT03083704 | Phase 1 | Feb 26, 2017 | Portola Pharmaceuticals |
| NCT03330457 | Phase 2 | Aug 30, 2015 | Portola Pharmaceuticals |
| NCT02329327 | Phase 3 | Jan 1, 2015 | McMaster University, Portola Pharmaceuticals |
| NCT02220725 | Phase 3 | May 1, 2014 | Portola Pharmaceuticals |
| NCT02207725 | Phase 3 | Mar 1, 2014 | Portola Pharmaceuticals |
| NCT03551730 | Phase 2 | Dec 31, 2012 | Portola Pharmaceuticals |
| NCT03551743 | Phase 2 | Dec 31, 2012 | Portola Pharmaceuticals |
| NCT03578146 | Phase 2 | Dec 31, 2012 | Portola Pharmaceuticals |
| NCT01758432 | Phase 2 | Dec 1, 2012 | Portola Pharmaceuticals |
| NCT03218241 | Phase 1 | Jun 30, 2012 | Portola Pharmaceuticals |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Portola Pharmaceuticals | For profit | 13 | 13 | 4 | 2012 |
| AstraZeneca | For profit | 2 | 2 | 2 | 2023 |
| McMaster University | Academic/Hospital | 2 | 0 | 2 | 2015 |
| Parexel | For profit | 1 | 0 | 1 | 2026 |
4 organizations
Page 1 / 1